{
    "nct_id": "NCT06810583",
    "official_title": "A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia",
    "inclusion_criteria": "* Aged less than or equal to 25 years at enrollment\n* Receiving treatment for AML or relapsed ALL at St. Jude and treatment is expected to cause prolonged (> 7 days) severe neutropenia (ANC < 500/ml)\n* Expected to receive care at St. Jude for at least 56 days following enrollment on the protocol\n* Female participant, greater than or equal to 9 years old, has a documented negative pregnancy test prior to receipt of study drug.\nHealthy volunteers allowed\nMust have maximum age of 25 Years",
    "exclusion_criteria": "* Allergy to vancomycin, dalbavancin, teicoplanin, levofloxacin or ciprofloxacin (Not including non-anaphylactic vancomycin infusion reaction)\n* Documented past or current infection or colonization with pathogenic bacteria resistant to vancomycin plus either ciprofloxacin or levofloxacin\n* Diagnosed with long QT syndrome\n* Any condition judged by the investigator to put the participant at high risk from participation\n* Suspected or proven active bacterial infection\n* Inability to complete requirements of participation in the study (in the opinion of the investigator)\n* Expected survival <28 days\n* Alkaline phosphatase, alanine transferase or total bilirubin â‰¥ 3x upper limit of normal for age\n* Estimated glomerular filtration rate (EGFR) <30 mL/minute/1.73 m2",
    "miscellaneous_criteria": ""
}